Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | GUSB | P08236 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21870593 | 0.80 | PIK3CD (0.52) | SMN1; SMN2PIK3CDPOLB | |
| SCHEMBL24750688 | 0.76 | KDM1A (0.33) | GBA1SMN1; SMN2 | |
| SCHEMBL23665093 | 0.76 | GBA1 (0.41) | GBA1SIGMAR1GUSB | |
| SCHEMBL29314332 | 0.76 | HRH3 (0.33) | GBA1PIK3CD | |
| SCHEMBL24233177 | 0.76 | GBA1 (0.33) | GBA1 | |
| SCHEMBL21870605 | 0.76 | PIK3CD (0.52) | SMN1; SMN2PIK3CDPOLB | |
| SCHEMBL22262762 | 0.75 | KDM4E (0.43) | GBA1 | |
| SCHEMBL21025208 | 0.75 | GBA1 (0.43) | GBA1SIGMAR1GUSB | |
| SCHEMBL11777036 | 0.75 | KDM4E (0.43) | GBA1 | |
| SCHEMBL16538653 | 0.74 | TSHR (0.35) | GBA1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | GBA1 2745/4885RORC 112/4885SMN1; SMN2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.